JP2014527400A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014527400A5 JP2014527400A5 JP2014517664A JP2014517664A JP2014527400A5 JP 2014527400 A5 JP2014527400 A5 JP 2014527400A5 JP 2014517664 A JP2014517664 A JP 2014517664A JP 2014517664 A JP2014517664 A JP 2014517664A JP 2014527400 A5 JP2014527400 A5 JP 2014527400A5
- Authority
- JP
- Japan
- Prior art keywords
- diabetes
- apociii
- population
- secreting cells
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161501480P | 2011-06-27 | 2011-06-27 | |
| US61/501,480 | 2011-06-27 | ||
| PCT/EP2012/062371 WO2013000920A2 (en) | 2011-06-27 | 2012-06-26 | Methods for treating and/or limiting development of diabetes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014527400A JP2014527400A (ja) | 2014-10-16 |
| JP2014527400A5 true JP2014527400A5 (https=) | 2015-06-11 |
| JP6242790B2 JP6242790B2 (ja) | 2017-12-06 |
Family
ID=46331358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014517664A Expired - Fee Related JP6242790B2 (ja) | 2011-06-27 | 2012-06-26 | 糖尿病の治療および／または発症抑制を行うための候補化合物を同定する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (6) | US8557513B2 (https=) |
| EP (1) | EP2724155B1 (https=) |
| JP (1) | JP6242790B2 (https=) |
| KR (1) | KR101937260B1 (https=) |
| CN (1) | CN103620404B (https=) |
| WO (1) | WO2013000920A2 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8557513B2 (en) * | 2011-06-27 | 2013-10-15 | Biocrine Ab | Methods for treating and/or limiting development of diabetes |
| JP6322209B2 (ja) | 2012-12-18 | 2018-05-09 | ビオクリネ エービー | 糖尿病の治療および／または発症抑制のための方法 |
| JP2014161257A (ja) * | 2013-02-22 | 2014-09-08 | Univ Of Tokyo | 多能性幹細胞から膵ランゲルハンス島を製造する方法 |
| AU2014218583A1 (en) | 2013-02-25 | 2015-10-15 | Imetabolic Biopharma, Llc | Apolipoprotein c3 (apociii) antagonists and methods of their use to remove apociii inhibition of lipoprotein lipase (lpl) |
| PL2970463T3 (pl) * | 2013-03-13 | 2018-04-30 | Biocrine Ab | Sposoby leczenia i/lub ograniczania rozwoju cukrzycy |
| KR20150046852A (ko) * | 2013-10-23 | 2015-05-04 | 삼성전자주식회사 | 전자 장치 및 전자 장치의 암호를 이용한 인증 방법 |
| KR102206054B1 (ko) * | 2014-05-09 | 2021-01-21 | 삼성전자주식회사 | 지문 처리 방법 및 그 전자 장치 |
| US9474951B2 (en) * | 2015-01-21 | 2016-10-25 | William Chuang | Golf tee structures, assemblies, and systems with improved accuracy |
| WO2016128358A1 (en) | 2015-02-09 | 2016-08-18 | Biocrine Ab | Methods for treating and/or limiting development of diabetes in subjects with amyotrophic lateral sclerosis |
| JP7341916B2 (ja) * | 2015-04-01 | 2023-09-11 | ビーエーエスエフ エーエス | アポｃ３を低下させるためのチアオキソ化合物の使用 |
| AU2017292184A1 (en) | 2016-07-08 | 2019-02-07 | Staten Biotechnology B.V. | Anti-Apoc3 antibodies and methods of use thereof |
| JP2020517242A (ja) | 2017-04-21 | 2020-06-18 | スターテン・バイオテクノロジー・ベー・フェー | 抗ＡｐｏＣ３抗体およびその使用方法 |
| US10538583B2 (en) | 2017-10-31 | 2020-01-21 | Staten Biotechnology B.V. | Anti-APOC3 antibodies and compositions thereof |
| KR20200074975A (ko) | 2017-10-31 | 2020-06-25 | 스태튼 바이오테크놀로지 비.브이. | 항-ApoC3 항체 및 이의 사용 방법 |
| JP2021530476A (ja) | 2018-07-19 | 2021-11-11 | バイオクライン アーベーBiocrine Ab | 糖尿病を治療するための方法および試薬 |
| US11310268B2 (en) | 2019-05-06 | 2022-04-19 | Secureworks Corp. | Systems and methods using computer vision and machine learning for detection of malicious actions |
| US11381589B2 (en) | 2019-10-11 | 2022-07-05 | Secureworks Corp. | Systems and methods for distributed extended common vulnerabilities and exposures data management |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6492325B1 (en) * | 1998-05-22 | 2002-12-10 | Boys Town National Research Hospital | Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease |
| US20030083242A1 (en) | 1998-11-06 | 2003-05-01 | Alphonse Galdes | Methods and compositions for treating or preventing peripheral neuropathies |
| CA2395136A1 (en) * | 1999-12-22 | 2001-06-28 | The Scripps Research Institute | Angiogenesis and vascular permeability modulators and inhibitors |
| EP1414491A4 (en) | 2001-07-09 | 2005-07-06 | Elan Pharm Inc | METHOD OF INHIBITING THE TOXICITY OF AMYLOID |
| ES2398110T3 (es) | 2003-04-29 | 2013-03-13 | Biocrine Ab | ApoCIII y tratamiento y diagnóstico de la diabetes |
| US20060094682A1 (en) * | 2004-10-29 | 2006-05-04 | Odyssey Thera, Inc. | Kinase inhibitors for the treatment of diabetes and obesity |
| WO2006110082A1 (en) * | 2005-04-11 | 2006-10-19 | Astrazeneca Ab | A method and a kit for diagnosing type 2 diabetes, metabolic syndrome, sub clinical atherosclerosis, myocardial infarct, stroke or clinical manifestations of diabetes. |
| US20090060843A1 (en) | 2007-08-31 | 2009-03-05 | Biocrine Ab | Non-Invasive In Vivo Imaging and Methods for Treating Type I Diabetes |
| US20110008901A1 (en) * | 2009-07-07 | 2011-01-13 | Kiernan Urban A | Apolipoprotein ciii in pre- and type 2 diabetes |
| US8557513B2 (en) * | 2011-06-27 | 2013-10-15 | Biocrine Ab | Methods for treating and/or limiting development of diabetes |
-
2012
- 2012-06-25 US US13/532,601 patent/US8557513B2/en not_active Expired - Fee Related
- 2012-06-26 CN CN201280028829.1A patent/CN103620404B/zh not_active Expired - Fee Related
- 2012-06-26 EP EP12729166.4A patent/EP2724155B1/en active Active
- 2012-06-26 WO PCT/EP2012/062371 patent/WO2013000920A2/en not_active Ceased
- 2012-06-26 KR KR1020147000028A patent/KR101937260B1/ko not_active Expired - Fee Related
- 2012-06-26 JP JP2014517664A patent/JP6242790B2/ja not_active Expired - Fee Related
-
2013
- 2013-09-13 US US14/026,145 patent/US9068973B2/en active Active
-
2015
- 2015-05-20 US US14/717,903 patent/US9353183B2/en active Active
-
2016
- 2016-01-14 US US14/995,645 patent/US20160194634A1/en not_active Abandoned
- 2016-01-14 US US14/995,341 patent/US9744232B2/en active Active
-
2017
- 2017-07-26 US US15/660,340 patent/US10226530B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014527400A5 (https=) | ||
| Bhattacharyya et al. | FibronectinEDA promotes chronic cutaneous fibrosis through Toll-like receptor signaling | |
| Takahashi et al. | Cancer cells co-opt the neuronal redox-sensing channel TRPA1 to promote oxidative-stress tolerance | |
| Wasserman et al. | The vasculature in prediabetes | |
| Xiao et al. | EZH2 enhances the differentiation of fibroblasts into myofibroblasts in idiopathic pulmonary fibrosis | |
| Omote et al. | Role of the TNF pathway in the progression of diabetic nephropathy in KK-Ay mice | |
| Varga et al. | Antitransforming growth factor-β therapy in fibrosis: recent progress and implications for systemic sclerosis | |
| Gil et al. | Heparanase is essential for the development of diabetic nephropathy in mice | |
| Chau et al. | MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways | |
| Zheng et al. | The coordinated roles of miR-26a and miR-30c in regulating TGFβ1-induced epithelial-to-mesenchymal transition in diabetic nephropathy | |
| Alimonti et al. | A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis | |
| Ren et al. | Nitric oxide synthase inhibition abolishes exercise-mediated protection against isoproterenol-induced cardiac hypertrophy in female mice | |
| Wettwer et al. | The new antiarrhythmic drug vernakalant: ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation | |
| Barlow et al. | Do skeletal muscle-secreted factors influence the function of pancreatic β-cells? | |
| Zhou et al. | Wnt/β-catenin signaling and renin–angiotensin system in chronic kidney disease | |
| Morales et al. | Inhibition of class I histone deacetylases blunts cardiac hypertrophy through TSC2-dependent mTOR repression | |
| Liu et al. | Circulating microRNA-146a and microRNA-21 predict left ventricular remodeling after ST-elevation myocardial infarction | |
| Ding et al. | New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis | |
| WO2013000920A3 (en) | Methods for identifying candidate compounds for treating and/or limiting development of diabetes | |
| Sayar et al. | EGFR inhibitors erlotinib and lapatinib ameliorate epidermal blistering in pemphigus vulgaris in a non‐linear, V‐shaped relationship | |
| Xue et al. | Activation of HIF-1 by metallothionein contributes to cardiac protection in the diabetic heart | |
| Lv et al. | Metabolic regulation of the glioblastoma stem cell epitranscriptome by malate dehydrogenase 2 | |
| Rosselot et al. | Myc is required for adaptive β-cell replication in young mice but is not sufficient in one-year-old mice fed with a high-fat diet | |
| Saito et al. | Mechanism of impairment on liver regeneration in elderly patients: role of hepatic stellate cell function | |
| Koga et al. | The bone morphogenic protein inhibitor, noggin, reduces glycemia and vascular inflammation in db/db mice |